Skip to content
2000
Volume 17, Issue 2
  • ISSN: 2589-9775
  • E-ISSN: 2589-9783

Abstract

Iatrogenic diseases, also referred to as drug-induced diseases (DIDs), represent a recognized yet inadequately investigated phenomenon that may result in enduring afflictions, hospital admissions, pharmacological interventions, protracted pharmaceutical reliance, and health complications. In the contemporary era of personalized medicine, it is imperative for prescribers to remain abreast of the dynamic advancements in the field of toxicology. Iatrogenic disorders may manifest as a result of medical interventions, including diagnostic procedures, therapeutic interventions, or preventative measures. Key factors to be taken into consideration encompass the patient's chronological age, dietary patterns, genetic predisposition, pre-existing medical conditions, diminished host response mechanisms, and pharmacological tolerance. Teratogenicity pertains to the prevalence of congenital anomalies and disorders resulting from exposure to teratogenic agents, environmental influences, and pharmacological interventions. The primary objective of this review is to provide individuals with comprehensive knowledge regarding the potential risks associated with iatrogenic diseases, thereby facilitating the prevention of unforeseen adverse outcomes.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdrr/10.2174/0125899775283761240118101649
2024-01-29
2025-09-20

  • From This Site

    /content/journals/cdrr/10.2174/0125899775283761240118101649
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. The Indian Pharmaceuticals Industry turnover has increased from 2.26 lakh crore rupees in 2017-2018 to over 3.44 lakh crore rupees in 2021-22.2023Available from: https://newsonair.gov.in/Main-News-Details.aspx?id=464886#:~:text=4%3A33PM-,Indian%20Pharmaceuticals%20Industry%20turnover%20increases%20from%20Rs%202.26%20lakh%20cr,lakh%20cr%20in%202021%2D22&text=The%20Indian%20Pharmaceuticals%20Industry%20turnover,crore%20rupees%20in%202021%2D22
  2. Annual turnover of Indian pharmaceutical market from 2015 to 2021, with estimates until 2030.Available from: https://www.statista.com/statistics/1037947/india-pharmaceutical-market-annual-turnover/ 2023
  3. KauravM. SinghA. Drug induced diseases and teratogenicity: An update.Ymer.2022211265466410.37896/YMER21.12/59
     [Google Scholar]
  4. Drug-Induced Diseases.In: Med India Medical Review2017
     [Google Scholar]
  5. SumaTK Drug induced diseases.AP J.201779435438
     [Google Scholar]
  6. PathanM LondheM JadhavD. Drug induced diseases.Int. J. Pharm. Res. Dev.202012060910.33545/26646862.2019.v1.i2a.8
     [Google Scholar]
  7. ClinardV. JenniferD.S. Drug induced diseases.US Pharm.2012374HS11HS18
     [Google Scholar]
  8. BreckenridgeAM Drug-induced cardiovascular disease.Drugs1979141294010.1136/bmj.1.6166.793
     [Google Scholar]
  9. DeglinSM DeglinJM ChungEK Drug-induced cardiovascular diseases.Drugs.1977141294010.2165/00003495‑197714010‑00002
     [Google Scholar]
  10. KelleniMT MahrousAB Drug induced cardiotoxicity: Mechanism, prevention and management.In: Cardiotoxicityintechopen2018
     [Google Scholar]
  11. KaplanA. Drug-induced skin disease.J. Allergy Clin. Immunol.198474457357910.1016/0091‑6749(84)90109‑X6238077
     [Google Scholar]
  12. SylviaL.M. Drug allergy, pseudoallergy, and cutaneous diseases.Drug-induced diseases: prevention, detection, and management.2nd ed TisdaleJ.E. MillerD.A. BethesdaAmerican Society of Health System Pharmacists20105197
     [Google Scholar]
  13. ModellW. Drug-induced diseases.Annu. Rev. Pharmacol.19655128530410.1146/annurev.pa.05.040165.00144114287885
     [Google Scholar]
  14. ShoukathU. KhatoonF. MahveenS. UddinM.N. Iatrogenic disease.Asian J. Pharm. Sci.20188211311610.5958/2231‑5691.2018.00020.5
     [Google Scholar]
  15. LaneR.J.M. RoutledgeP.A. Drug-induced neurological disorders.Drugs198326212414710.2165/00003495‑198326020‑000026349966
     [Google Scholar]
  16. DavisonW. Neurological and mental disturbances due to drugs.Age Ageing.197811913010.1093/ageing/7.suppl.119
     [Google Scholar]
  17. UppalP. LaPlanteK.L. GaitanisM.M. JankowichM.D. WardK.E. Daptomycin-induced eosinophilic pneumonia - a systematic review.Antimicrob. Resist. Infect. Control2016515510.1186/s13756‑016‑0158‑827999664
     [Google Scholar]
  18. CooperJ A D.Jr ZitnikR.J. MatthayR.A. Mechanisms of drug-induced pulmonary disease.Annu. Rev. Med.198839139540410.1146/annurev.me.39.020188.0021432453156
     [Google Scholar]
  19. TripathiK.D. Essentials of medical pharmacology.8th edNew DelhiJaypee Brothers Medical2018
     [Google Scholar]
  20. PhilpottH.L. NandurkarS. LubelJ. GibsonP.R. Drug-induced gastrointestinal disorders.Frontline Gastroenterol.201451495710.1136/flgastro‑2013‑10031628839751
     [Google Scholar]
  21. BartoliE. Adverse effects of drugs on the kidney.Eur. J. Intern. Med.2016281810.1016/j.ejim.2015.12.00126725327
     [Google Scholar]
  22. Ghane ShahrbafF. AssadiF. Drug-induced renal disorders.J. Renal Inj. Prev.201543576010.12861/jrip.2015.1226468475
     [Google Scholar]
  23. NaughtonC.A. Drug-induced nephrotoxicity.Am. Fam. Physician200878674375018819242
     [Google Scholar]
  24. MaR.C.W. KongA.P.S. ChanN. TongP.C.Y. ChanJ.C.N. Drug-induced endocrine and metabolic disorders.Drug Saf.200730321524510.2165/00002018‑200730030‑0000517343430
     [Google Scholar]
  25. KaravitakiN. Diagnosis of endocrine disease: Drug-induced endocrinopathies and diabetes: A combo-endocrinology overview .Eur. J. Endocrinol.20193110.1530/EJE‑19‑0154
     [Google Scholar]
  26. BohannonA.D. LylesK.W. Drug-induced bone disease.Clin. Geriatr. Med.199410461162310.1016/S0749‑0690(18)30319‑77850693
     [Google Scholar]
  27. Wolinsky-FriedlandM. Drug-induced metabolic bone disease.Endocrinol. Metab. Clin. North Am.199524239542010.1016/S0889‑8529(18)30046‑X7656896
     [Google Scholar]
  28. SachdevaP. PatelB.G. PatelB.K. Drug use in pregnancy; a point to ponder!Indian J. Pharm. Sci.20097111710.4103/0250‑474X.5194120177448
     [Google Scholar]
  29. JamkhandeP.G. ChintawarK.D. ChandakP.G. Teratogenicity: A mechanism based short review on common teratogenic agents.Asian Pac. J. Trop. Dis.20144642143210.1016/S2222‑1808(14)60600‑9
     [Google Scholar]
  30. Appendix DTeratogens/prenatal substance abuse.In: Understanding Genetics: A District of Columbia Guide for Patients and Health Professionals.Washington (DC)Genetic Alliance2010
     [Google Scholar]
  31. NwokeM. The effects of teratogens on the health of developing human beings.Paper Presented at the 8th Biennial International Conference on Alcohol, Drugs and Society in Africa, HeldCentral Area, Abuja23-25th July, 20082008
     [Google Scholar]
  32. What are Birth Defects?Available from: https://www.cdc.gov/ncbddd/birthdefects/facts.html
  33. ChaudharyN. RavatS.H. ShahP.U. Phenytoin induced dyskinesia.Indian Pediatr.19983532742769707885
     [Google Scholar]
  34. OwusuA.G. AnkrahD. Drug-drug-induced akathisia: Two case reports.Case Rep. Psychiatry202020201510.1155/2020/964948332373382
     [Google Scholar]
  35. JainN. SharmaD. AgrawalR. JainA. A newborn with teratogenic effect of imatinib mesylate: A very rare case report.Med. Princ. Pract.201524329129310.1159/00038180625896670
     [Google Scholar]
  36. GoyalM. GuptaA. SharmaM. MathurP. BansalN. Fetal valproate syndrome with limb defects: An Indian case report.Case Rep. Pediatr.201620161410.1155/2016/349591028003925
     [Google Scholar]
  37. ClausonK.A. Drug-induced diseases: Prevention, detection, and management.Am. J. Pharm. Educ.2006706148
     [Google Scholar]
  38. OlesenL.L. JensenT.S. Prevention and management of drug-induced peripheral neuropathy.Drug Saf.19916430231410.2165/00002018‑199106040‑000071653573
     [Google Scholar]
  39. AlcalaM. BoladoV.E. Sánchez-VeraI. ClapésS. DasíF. SáezG. CarreraE. Alvarez-GallegoF. LoekenM.R. VianaM. Prevention of teratogenesis in pregnancies of obese rats by vitamin E supplementation.Antioxidants2021108117310.3390/antiox1008117334439421
     [Google Scholar]
  40. ShroukhW.A. SteinkeD.T. WillisS.C. Risk management of teratogenic medicines: A systematic review.Birth Defects Res.2020112201755178610.1002/bdr2.179932918401
     [Google Scholar]
/content/journals/cdrr/10.2174/0125899775283761240118101649
Loading
Unravelling the Complex Interplay: Understanding Drug-induced Diseases and Teratogenicity from a Comprehensive Perspective
Current Drug Research Reviews 17, 254 (2025); https://doi.org/10.2174/0125899775283761240118101649
/content/journals/cdrr/10.2174/0125899775283761240118101649
/content/journals/cdrr/10.2174/0125899775283761240118101649
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): adverse drug reactions; birth defects; Drug-induced diseases; iatrogenic diseases; teratogenic agents; teratogenicity

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test